However, the outcomes from the clinical trials indicate that the bacteria alone are not sufficient to stop the progression of cancer [20]; additional engineering of cancer-killing (e.g., TNF-α) or induction of cancer-killing (such as antigen) gene is required for the development of successful oncology drug [21]. The gene discussed is TNF; the disease is cancer.